TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06083129
Drug: Grafalon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
Study: NCT06249867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
Study: NCT00005015
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06532279
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT05784051
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
Study: NCT05784051
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients of this group have no therapeutic or no treatment modification such as drug therapy
Study: NCT05446688
Drug: 6MW3211
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MW3211 injection, 45mg/kg, Q2W
Study: NCT05205447
Drug: LY3410738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LY3410738
Study: NCT05638854
Drug: ZB002
Normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
Study: NCT05638854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Study: NCT05949632
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm description
Study: NCT06477185
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
Study: NCT06477185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
Study: NCT06366789
Drug: ZE46-0134
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules QD
Study: NCT04864496
Drug: Prescribe placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: manufactured by Daroo Salamat Pharmed, two times daily
Study: NCT05323201
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 i.v. for once (Day -5)
Study: NCT04984954
Drug: MUSK pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
Study: NCT05831930
Drug: Nituozumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
Study: NCT06056167
Drug: Degludec insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol.
Study: NCT04530864
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
Study: NCT04525274
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.
Study: NCT05722691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once intramuscular injection (1 vial)
Study: NCT05077332
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg (initial dose) then 200 mg capsule, BID for 5 days
Study: NCT06006689
Drug: Qishen Yiqi Dripping Pills placebo 3 bags
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT05841160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04690283
Drug: Mimetic granules of Yiqi-Wenjing prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
Study: NCT04690283
Drug: Huangqi-Guizhi-Wuwu granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
Study: NCT05159908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral administration
Study: NCT05645913
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
Study: NCT06297096
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Study: NCT05825092
Drug: Androgel Topical Product
Normalized name: Androgel Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
Study: NCT06232096
Drug: MBS314 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ.
Study: NCT05344729
Drug: TQB3616 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
Study: NCT05677152
Drug: Intravenous Infusion of Aclasta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
Study: NCT05338463
Drug: Fespixon Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks
Study: NCT05825092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
Study: NCT05167071
Drug: HBM4003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
Study: NCT02502370
Drug: observation alone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02502370
Drug: LV5FU2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02502370
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06222801
Drug: Tumor necrosis factor alpha
Normalized name: Tumor necrosis factor alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor agent. Immunomodulatory agent.
Study: NCT04871464
Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06340789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the add-on placebo with conventional pharmacological treatment
Study: NCT05943223
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative normal saline 50 mL once daily
Study: NCT05791721
Drug: Etoricoxib 90 Mg Oral Tablet
Normalized name: etoricoxib 90 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
Study: NCT04999098
Drug: Echinaforce Forte tablets
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients
Study: NCT04999098
Drug: Echinaforce Chewable tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients
Study: NCT04999098
Drug: Echinaforce tincture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)
Study: NCT06475443
Drug: pyrotinib plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT05624294
Drug: CS0159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05624294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05508516
Drug: Shugan Dingtong decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
Study: NCT05072990
Drug: Chinese herb medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
Study: NCT06028256
Drug: Norepinephrine Hydrochloride
Normalized name: ethylnorepinephrine hydrochloride
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
Study: NCT06028256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
Study: NCT04795141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline for injection
Study: NCT04896658
Drug: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug
Study: NCT06066008
Drug: ZM-01-L
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV-hRS1 intravitreal injection of low dose
Study: NCT05760053
Drug: EP/EC+PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
Study: NCT06429475
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
Study: NCT05927857
Drug: nal-IRI /Experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
Study: NCT05927857
Drug: Trifluridine/Tipiracil /Experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
Study: NCT04959305
Drug: HCP1803-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04959305
Drug: RLD2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04959305
Drug: RLD2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04959305
Drug: RLD2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04959305
Drug: HPP2003-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT04959305
Drug: HPP2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT05676073
Drug: SHEN26 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study: NCT05676073
Drug: SHEN26 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study: NCT05676073
Drug: SHEN26 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study: NCT06185361
Drug: Fluoxetine 20 MG
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine
Study: NCT04984525
Drug: SYNB1618
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1618 is formulated as a nonsterile solution intended for oral administration
Study: NCT05780554
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
Study: NCT05780554
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
Study: NCT05725343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Study: NCT05920005
Drug: candesartan cilexetil + chlorthalidone + amlodipine
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
Study: NCT05920005
Drug: Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
Study: NCT04775030
Drug: CBD occlusal appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
Study: NCT06394336
Drug: Standard treatment (oral analgesic/anti-inflammatory drug)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral analgesic/anti-inflammatory drug. Education.
Study: NCT06041204
Drug: Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet
Normalized name: levothyroxine 25 mcg (0.025 mg) oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
Study: NCT04076748
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
Study: NCT06234397
Drug: BH3120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
Study: NCT06298032
Drug: Olamkicept Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg
Study: NCT06298032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05644496
Drug: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Normalized name: bupivacaine-meloxicam 400 mg-12 mg/14 mL injectable solution, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
Study: NCT04976036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Study: NCT04913831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline 100ml, 8-35 days, once/day, intravenous administration
Study: NCT06485440
Drug: Dysport 300 UNT Injection
Normalized name: Dysport 300 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
Study: NCT06508749
Drug: VRC07-523LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Antibody Infusion based on subject's weight
Study: NCT06322953
Drug: Direct-Acting Oral Anticoagulants (used as per local standard practice)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting oral anticoagulants to be prescribed as per local standard practice at either 1 or 4 weeks.
Study: NCT00729768
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating doses
Study: NCT04654065
Drug: IN-C004
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of IN-C004 taken orally.
Study: NCT06494072
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.